We selected 46 patients with advanced oesophageal squamous cell carcinoma...The oral treatment of apatinib in the VEGFR-2 and NF-kB positive groups was better than that in the negative groups. The partial remission rate of patients was 26.09%, and the disease control rate was 67.39%....The median progression-free survival was 3.7 months and the median overall survival was 7.2 months.